Print

HIV-POL-001

Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-Negative 18-50 Year Old Healthy Volunteers

Trial Details:

I Completed
Bavarian Nordic October 01, 2006
MVA-mBN32 Gag, Pol, Vpr, Nef, Rev, Env 21 CTL epitopes
MVA-mBN32 Viral Vector - Pox
Germany 36
NCT00386633
http://clinicaltrials.gov/ct/show/NCT00386633?order=1